Novartis AG EBITDA 2010-2024 | NVS

Novartis AG EBITDA for the quarter ending June 30, 2024 was $4.014B, a 43% increase year-over-year.

  • Novartis AG 2023 EBITDA was 18.152B, a 21.74% increase from 2022.
  • Novartis AG 2022 EBITDA was 14.911B, a 27.56% increase from 2021.
  • Novartis AG 2021 EBITDA was 11.689B, a 28.2% decline from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Novartis AG EBITDA 2010-2024 | NVS

  • Novartis AG 2023 EBITDA was 18.152B, a 21.74% increase from 2022.
  • Novartis AG 2022 EBITDA was 14.911B, a 27.56% increase from 2021.
  • Novartis AG 2021 EBITDA was 11.689B, a 28.2% decline from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$861.3B
Novo Nordisk (NVO)$592.4B
Johnson & Johnson (JNJ)$402.2B
AbbVie (ABBV)$341.7B
Merck (MRK)$299.6B
AstraZeneca (AZN)$243.5B
Pfizer (PFE)$169B
Sanofi (SNY)$144.1B
Innoviva (INVA)$1.2B